Jubilant Pharmova-led subsidiary Jubilant Pharma has announced that it has received a favourable and unanimous judgment from the United States Court of Appeals summarily affirming Jubilant’s earlier favourable rulings from the US Patent Office (“PTAB”) and the US International Trade Commission (“ITC”). These two rulings by the Appellate Court denied the appeals filed by Bracco Diagnostics, Inc (“Bracco”).
“The favourable ruling by the United States Court of Appeals further confirms Jubilant’s right to continue development and commercialization of RUBY-FILL in the U.S. marketplace and to continue focusing on our goal of bringing innovative products to the market for patients in need of the latest technology," said Pramod Yadav, CEO, Jubilant Pharma Limited.
Sergio Calvo, President of Jubilant’s Radiopharmaceuticals Division, said that the rulings demonstrate the uniqueness of our RUBY-FILL Generator and Elution system and its intellectual property and the strength of our research and development efforts.
As per the regulatory filing, Jubilant successfully challenged Bracco’s patent infringement claims in an Inter Parties Review (IPR) proceeding before the U.S. Patent Office as well as in a separate proceeding in the ITC. In both instances, Jubilant was successful.
Despite the rulings of both the PTAB and the ITC, Bracco filed appeals to the US Court of Appeals in Washington D.C. These appeals are now dismissed.
At around 1.59 pm, Jubilant Pharmova was trading at Rs842.45 per piece up by 0.8% on Sensex.